Roche/Genentech doubles down on tau, fronting $120M cash to ally on a 2-pronged strategy to fight Alzheimer’s
After butting up against repeated failures on the amyloid beta side of the R&D strategy for fighting Alzheimer’s, Roche is once again turning to the runner-up target that has been getting an increased focus in the hopes of finding something — anything — that can slow the progress of this disease.
The terms of the deal include $120 million upfront for UCB, plus potential development and sales milestones, cost reimbursement and royalties totaling nearly $2 billion. UCB will fund and conduct a proof-of-concept study in Alzheimer’s, and with the results in hand, Genentech, a Roche subsidiary, can either return the rights to UCB or push ahead in a drive to the market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.